NDA 210867 · Mdgh
Moxidectin
Moxidectin · Oral
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jun 13, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
24
10 Phase 3, 2 recruiting
FAERS reports
3
3 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 30, 2026.
Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in adult and pediatric patients aged 4 years and older and weighing at least 13 kg [see Clinical Studies ( 14 )] . Limitations of Use: Moxidectin Tablets does not kill adult Onchocerca volvulus (O. volvulus) parasites . Follow-up evaluation is advised. The safety and efficacy of repeat administration of Moxidectin Tablets in patients with O . volvulus has not been studied. Moxidectin is an anthelmintic indicated for the treatment of onchocerciasis due to Onchocerca volvulus in adults and pediatric patients aged 4 years and older and weighing at least 13 kg. ( 1 ) Limitations of Use: Moxidectin Tablets do not kill adult Onchocerca volvulus (O. volvulus) parasites. Follow-up is advised. ( 1 ) The safety and efficacy of repeat administration of Moxidectin Tablets in patients with O . volvulus has not been studied. ( 1 )
Mechanism: Moxidectin, a macrocyclic lactone, is an anthelmintic drug [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 7, 2025 Supplement 6 · Efficacy · priority review OrphanLetterLabel
- Jun 13, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- MOXIDECTIN · MOXIDECTIN 2MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Moxidectin" as an intervention, any sponsor and status, largest first.
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical DiseasesPivotal-lookingRecruiting
Kirby InstituteGovernment (non-federal)
NCT07145736 · 52,000 participants (planned) · Start Aug 4, 2025 · Primary completion Mar 31, 2029
Drug: Moxidectin; Ivermectin · For: Onchocerciasis; Ascaris Lumbricoides Infection; Trichuris Trichiura; Infection and 2 more
Sites: Andulo, Angola
Medicines Development for Global HealthAcademic, hospital or other
NCT04311671 · 12,979 participants · Start May 3, 2021 · Primary completion Sep 27, 2024
Drug: Moxidectin; Ivermectin and 1 more · For: Onchocerciasis
Sites: Abidjan, Côte d’Ivoire; Rethy, Democratic Republic of the Congo
- Better Options for Lymphatic Filariasis TreatmentPivotal-lookingRecruiting
Medicines Development for Global HealthAcademic, hospital or other
NCT07159373 · 5,100 participants (planned) · Start Sep 28, 2026 · Primary completion Jun 2027
Drug: MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole; IDA - Ivermectin + DEC + albendazole · For: Lymphatic Filariasis; Scabies; Strongyloidiasis
Sites: Suva, Fiji
- Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus InfectionPivotal-lookingCompleted
Medicines Development for Global HealthAcademic, hospital or other
NCT00790998 · 1,497 participants · Start Apr 2009 · Primary completion Feb 2012
Drug: Moxidectin; Ivermectin · For: Onchocerciasis
Sites: Butembo, Democratic Republic of the Congo; Rethy, Democratic Republic of the Congo; Hohoe, Ghana · 4 sites in all
- Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides StercoralisPivotal-lookingCompleted
Jennifer KeiserAcademic, hospital or other
NCT04056325 · 617 participants · Start Nov 27, 2019 · Primary completion Apr 30, 2021
Drug: Moxidectin; Ivermectin and 1 more · For: Strongyloides Stercoralis Infection
Sites: Vientiane, Laos
- Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administrationPivotal-lookingCompleted
Jennifer KeiserAcademic, hospital or other
NCT04700423 · 536 participants · Start Mar 1, 2021 · Primary completion Aug 18, 2021
Drug: moxidectin (8 mg) / albendazole (400 mg); ivermectin (200 µg/kg) / albendazole (400 mg) and 3 more · For: Trichuriasis; Ascariasis; Hookworm Infections and 1 more
Sites: Chake Chake, Tanzania
- Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides StercoralisPivotal-lookingCompleted
Jennifer KeiserAcademic, hospital or other
NCT04848688 · 332 participants · Start Feb 5, 2022 · Primary completion Jul 17, 2022
Drug: Moxidectin 2 mg; Ivermectin 3 mg and 1 more · For: Strongyloides Stercoralis Infection
Sites: Phnom Penh, Cambodia
- Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisPivotal-lookingActive, not recruiting
Medicines Development for Global HealthAcademic, hospital or other
NCT03876262 · 323 participants · Start May 3, 2021 · Primary completion Jul 31, 2024
Drug: Moxidectin; Ivermectin · For: Onchocerciasis
Sites: Rethy, Democratic Republic of the Congo
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- abortion spontaneous1
- biliary obstruction1
- dehydration1
- fall1
- hepatic encephalopathy1
- hepatitis fulminant1
- multiple drug overdose accidental1
- somnolence1
- wrong drug administered1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug.
Tang M, Hu X, Wang Y, et al. · Pharmacol Res 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Egg reappearance periods of anthelmintics against equine cyathostomins: The state of play revisited.
Macdonald SL, Abbas G, Ghafar A, et al. · Int J Parasitol Drugs Drug Resist 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.
Tan B, Opoku N, Attah SK, et al. · PLoS Negl Trop Dis 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Anthelmintic intoxication in goats and sheep: A systematic review.
Oliveira CC, Costa DFL, Limeira CH, et al. · Res Vet Sci 2022 · Systematic Review
- Critically appraised topic for the most effective and safe treatment for canine generalised demodicosis.
Perego R, Spada E, Foppa C, et al. · BMC Vet Res 2019 · Systematic Review
- Dermatobia hominis: Potencial risk of resistance to macrocyclic lactones.
das Neves JH, Carvalho N, Amarante AF · Vet Parasitol 2015 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Mdgh
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.